{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T15:05:47Z","timestamp":1764860747445,"version":"3.46.0"},"reference-count":68,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>\n                      VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is a newly discovered, adult-onset, hemato-inflammatory disease driven by clonal dominance of pro-inflammatory hematopoietic cells bearing a somatic mutation in the\n                      <jats:italic toggle=\"yes\">UBA1<\/jats:italic>\n                      gene. This review aims to integrate and discuss the most recent insights into the evolving understanding of VEXAS pathogenesis and clinical management.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>An interplay between inflammation and clonal dominance of UBA1 mutant hematopoietic clones underlies the pathogenesis of VEXAS syndrome. Mutant cells both generate and sustain a toxic inflammatory milieu that impairs wild-type hematopoiesis. Despite exhibiting dysfunctional differentiation, VEXAS cells activate pro-survival pathways that support their persistence and progressive dominance.<\/jats:p>\n                    <jats:p>Recent international guidelines offer evidence-based recommendations to optimize therapy and manage both inflammatory and hematologic features of the disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>This review dissects the key molecular mechanisms driving inflammation and clonal survival in UBA1 mutant cells, and outlines current therapeutic strategies proposed to counteract VEXAS progression and improve patient outcomes. The recent findings presented here, along with the deeper understanding that will be built upon them, not only advance the knowledge of the disease pathobiology, but also pave the way for more precise, mechanism-driven treatment approaches aimed at intercepting disease progression and improving long-term outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000001137","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:00:07Z","timestamp":1761998407000},"page":"45-52","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Decoding VEXAS syndrome: emerging insights into pathogenesis and clinical management"],"prefix":"10.1097","volume":"38","author":[{"given":"Martina","family":"Fiumara","sequence":"first","affiliation":[{"name":"San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute"},{"name":"Vita-Salute San Raffaele University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corrado","family":"Campochiaro","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University"},{"name":"Unit of Immunology, Rheumatology, Allergy and Rare Diseases"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Molteni","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University"},{"name":"Inflammation Fibrosis and Ageing Initiative (INFLAGE), Division of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"R1-20251204","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease","volume":"383","author":"Beck","year":"2020","journal-title":"N Engl J Med"},{"key":"R2-20251204","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1001\/jama.2022.24836","article-title":"Estimated prevalence and clinical manifestations of UBA1 variants associated with VEXAS syndrome in a clinical population","volume":"329","author":"Beck","year":"2023","journal-title":"JAMA"},{"key":"R3-20251204","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3324\/haematol.2021.280238","article-title":"VEXAS syndrome in a female patient with constitutional 45,X (Turner syndrome)","volume":"107","author":"Stubbins","year":"2022","journal-title":"Haematologica"},{"key":"R4-20251204","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/17474086.2025.2508505","article-title":"Clonal hematopoiesis meets an autoinflammatory disease: the new paradigm of VEXAS syndrome","volume":"18","author":"Fiumara","year":"2025","journal-title":"Expert Rev Hematol"},{"key":"R5-20251204","doi-asserted-by":"crossref","first-page":"5217","DOI":"10.1093\/rheumatology\/keaf293","article-title":"Clinical Features in VEXAS syndrome: a systematic review","volume":"64","author":"Al-Hakim","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"R6-20251204","doi-asserted-by":"crossref","first-page":"5217","DOI":"10.1093\/rheumatology\/keaf293","article-title":"Clinical features in VEXAS syndrome: a systematic review","volume":"64","author":"Al-Hakim","year":"2025","journal-title":"Rheumatology"},{"key":"R7-20251204","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1182\/bloodadvances.2021004976","article-title":"Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1","volume":"5","author":"Obiorah","year":"2021","journal-title":"Blood Adv"},{"key":"R8-20251204","first-page":"244","article-title":"Spectrum of clonal hematopoiesis in VEXAS syndrome","volume":"142","author":"Gutierrez-Rodrigues","year":"2023","journal-title":"Blood"},{"key":"R9-20251204","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nrm.2017.83","article-title":"Post-translational modifications: ubiquitylation at the crossroads of development and disease","volume":"19","author":"Rape","year":"2018","journal-title":"Nat Rev Mol Cell Biol"},{"key":"R10-20251204","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrm2673","article-title":"Ubiquitin-like protein activation by E1 enzymes: The apex for downstream signalling pathways","volume":"10","author":"Schulman","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"key":"R11-20251204","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev-cellbio-100617-062802","article-title":"Principles of ubiquitin-dependent signaling","volume":"34","author":"Oh","year":"2018","journal-title":"Annu Rev Cell Dev Biol"},{"key":"R12-20251204","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41584-022-00778-4","article-title":"Disorders of ubiquitylation: unchained inflammation","volume":"18","author":"Beck","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"R13-20251204","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.aax3769","article-title":"Cellular quality control by the ubiquitin-proteasome system and autophagy","volume":"366","author":"Pohl","year":"2019","journal-title":"Science"},{"key":"R14-20251204","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.semcdb.2023.08.002","article-title":"Proteotoxic stress and the ubiquitin proteasome system","volume":"156","author":"Kandel","year":"2024","journal-title":"Semin Cell Dev Biol"},{"key":"R15-20251204","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1073\/pnas.95.6.2727","article-title":"The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death","volume":"95","author":"Ciechanover","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"R16-20251204","doi-asserted-by":"crossref","first-page":"4789","DOI":"10.1038\/s41467-022-32040-6","article-title":"Structures of UBA6 explain its dual specificity for ubiquitin and FAT10","volume":"13","author":"Truongvan","year":"2022","journal-title":"Nat Commun"},{"key":"R17-20251204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-022-32613-5","article-title":"Crystal structures reveal catalytic and regulatory mechanisms of the dual-specificity ubiquitin\/FAT10 E1 enzyme Uba6","volume":"13","author":"Yuan","year":"2022","journal-title":"Nat Commun"},{"key":"R18-20251204","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s00018-022-04215-3","article-title":"Targeting the E1 ubiquitin-activating enzyme (UBA1) improves elexacaftor\/tezacaftor\/ivacaftor efficacy towards F508del and rare misfolded CFTR mutants","volume":"79","author":"Borgo","year":"2022","journal-title":"Cell Mol Life Sci"},{"key":"R19-20251204","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1182\/blood.2022016985","article-title":"Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis","volume":"140","author":"Ferrada","year":"2022","journal-title":"Blood"},{"key":"R20-20251204","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1001\/jamadermatol.2024.1657","article-title":"Skin manifestations of VEXAS syndrome and associated genotypes","volume":"160","author":"Tan","year":"2024","journal-title":"JAMA Dermatol"},{"key":"R21-20251204","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1093\/rheumatology\/keaf094","article-title":"VEXAS syndrome through a rheumatologist's lens: insights from a Spanish national cohort","volume":"64","author":"Garc\u00eda-Escudero","year":"2025","journal-title":"Rheumatology"},{"key":"R22-20251204","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1182\/blood.2020010177","article-title":"Therapeutic options in VEXAS syndrome: insights from a retrospective series","volume":"137","author":"Bourbon","year":"2021","journal-title":"Blood"},{"key":"R23-20251204","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood.2020010286","article-title":"Novel somatic mutations in UBA1 as a cause of VEXAS syndrome","volume":"137","author":"Poulter","year":"2021","journal-title":"Blood"},{"key":"R24-20251204","doi-asserted-by":"crossref","first-page":"e435","DOI":"10.1093\/rheumatology\/keab524","article-title":"Atypical splice-site mutations causing VEXAS syndrome","volume":"60","author":"Templ\u00e9","year":"2021","journal-title":"Rheumatology"},{"key":"R25-20251204","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/s44318-024-00046-z","article-title":"Shared and distinct mechanisms of UBA1 inactivation across different diseases","volume":"43","author":"Collins","year":"2024","journal-title":"EMBO J"},{"key":"R26-20251204","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1002\/art.42471","article-title":"Novel somatic UBA1 variant in a patient With VEXAS syndrome","volume":"75","author":"Stiburkova","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"R27-20251204","doi-asserted-by":"crossref","first-page":"E868","DOI":"10.1097\/HS9.0000000000000868","article-title":"Recurrent mutations of the active adenylation domain of UBA1 in atypical form of VEXAS syndrome","volume":"7","author":"Faurel","year":"2023","journal-title":"Hemasphere"},{"key":"R28-20251204","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/jha2.1016","article-title":"VEXAS without vacuoles: linking genotype to phenotype","volume":"5","author":"Zhukovsky","year":"2024","journal-title":"EJHaem"},{"key":"R29-20251204","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/s41591-025-03623-9","article-title":"Mechanisms of hematopoietic clonal dominance in VEXAS syndrome","volume":"31","author":"Molteni","year":"2025","journal-title":"Nat Med"},{"key":"R30-20251204","article-title":"Single-cell genotype-phenotype mapping identifies therapeutic vulnerabilities in VEXAS syndrome","author":"Ganesan","year":"2024","journal-title":"bioRxiv"},{"key":"R31-20251204","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1038\/s41467-025-59890-0","article-title":"In depth transcriptomic profiling defines a landscape of dysfunctional immune responses in patients with VEXAS syndrome","volume":"16","author":"Mizumaki","year":"2025","journal-title":"Nat Commun"},{"key":"R32-20251204","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2025029081","article-title":"VEXAS anemia is a mosaic erythroblastopenia","author":"Rodrigues","year":"2025","journal-title":"Blood"},{"key":"R33-20251204","doi-asserted-by":"crossref","first-page":"101160","DOI":"10.1016\/j.xcrm.2023.101160","article-title":"Early activation of inflammatory pathways in UBA1-mutated hematopoietic stem and progenitor cells in VEXAS","volume":"4","author":"Wu","year":"2023","journal-title":"Cell Rep Med"},{"key":"R34-20251204","doi-asserted-by":"crossref","DOI":"10.1172\/JCI193011","article-title":"UBA1-depleted neutrophils disrupt immune homeostasis and induce VEXAS-like autoinflammatory disease in mice","author":"Dong","year":"2025","journal-title":"J Clin Invest"},{"key":"R35-20251204","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1093\/rheumatology\/keaf284","article-title":"Recapitulation of clinical features in a patient-derived xenograft mouse model of VEXAS syndrome","volume":"64","author":"Arede","year":"2025","journal-title":"Rheumatology"},{"key":"R36-20251204","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/s41375-025-02671-x","article-title":"Characterization of E1 enzyme dependencies in mutant-UBA1 human cells reveals UBA6 as a novel therapeutic target in VEXAS syndrome","volume":"39","author":"Clough","year":"2025","journal-title":"Leukemia"},{"key":"R37-20251204","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/s41467-024-44811-4","article-title":"VEXAS syndrome is characterized by inflammasome activation and monocyte dysregulation","volume":"15","author":"Kosmider","year":"2024","journal-title":"Nat Commun"},{"issue":"(Suppl 1)","key":"R38-20251204","first-page":"187","article-title":"The mechanism of cell autonomous inflammation in VEXAS syndrome is mediated by proteotoxic stress","volume":"144","author":"BJ Proteotoxic Stress Samuel Magaziner","year":"2024","journal-title":"Blood"},{"key":"R39-20251204","doi-asserted-by":"crossref","first-page":"e70244","DOI":"10.1111\/1756-185X.70244","article-title":"VEXAS syndrome: phenotype alteration in the long-term disease duration","volume":"28","author":"Sun","year":"2025","journal-title":"Int J Rheum Dis"},{"key":"R40-20251204","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s11658-025-00691-0","article-title":"VEXAS, Chediak\u2013Higashi syndrome and Danon disease: myeloid cell endo-lysosomal pathway dysfunction as a common denominator?","volume":"30","author":"Savy","year":"2025","journal-title":"Cell Mol Biol Lett"},{"key":"R41-20251204","doi-asserted-by":"crossref","first-page":"rkae065","DOI":"10.1093\/rap\/rkae065","article-title":"Targeting enhanced cell death represents a potential therapeutic strategy for VEXAS syndrome","volume":"8","author":"Adachi","year":"2024","journal-title":"Rheumatol Adv Pract"},{"key":"R42-20251204","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1182\/blood.2024028216","article-title":"Impaired cytotoxic function and exhausted phenotype of natural killer cells in VEXAS syndrome","volume":"146","author":"Breillat","year":"2025","journal-title":"Blood"},{"issue":"(Suppl 1)","key":"R43-20251204","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1182\/blood-2024-208122","article-title":"Vexas syndrome is a new cause of p53-mediated erythroblastopenia","volume":"144","author":"Rodrigues","year":"2024","journal-title":"Blood"},{"key":"R44-20251204","doi-asserted-by":"crossref","DOI":"10.1002\/art.43287","article-title":"American College of Rheumatology guidance statement for diagnosis and management of VEXAS developed by the International VEXAS Working Group Expert Panel","author":"Mekinian","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"R45-20251204","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1016\/S2665-9913(25)00034-7","article-title":"Treatment outcomes in patients with VEXAS syndrome: a retrospective cohort study","volume":"7","author":"Al-Hakim","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"R46-20251204","doi-asserted-by":"crossref","first-page":"1462254","DOI":"10.3389\/fphar.2025.1462254","article-title":"Efficacy and safety profile of biotechnological agents and Janus kinase inhibitors in VEXAS syndrome: data from the international AIDA Network VEXAS registry","volume":"16","author":"Vitale","year":"2025","journal-title":"Front Pharmacol"},{"key":"R47-20251204","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/art.42101","article-title":"Successful use of cyclosporin A and interleukin-1 blocker combination therapy in VEXAS syndrome: a single-center case series","volume":"74","author":"Campochiaro","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"R48-20251204","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1136\/ard-2024-225640","article-title":"Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX","volume":"83","author":"Hadjadj","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R49-20251204","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ard.2025.05.769","article-title":"POS0383 IL-1 Inhibition in patients with vexas syndrome \u2013 a retrospective international multicenter study","volume":"84","author":"Eviatar","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R50-20251204","doi-asserted-by":"crossref","first-page":"107584","DOI":"10.1016\/j.leukres.2024.107584","article-title":"Association between myeloid disorders and adult onset-inflammatory syndromes, successful treatment with JAK-inhibitors: case series and literature review","volume":"146","author":"Mishra","year":"2024","journal-title":"Leuk Res"},{"key":"R51-20251204","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2147\/OARRR.S531094","article-title":"Promise of Jak inhibition in the management of VEXAS, case report with review of the literature","volume":"17","author":"Alnahas","year":"2025","journal-title":"Open Access Rheumatol"},{"key":"R52-20251204","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/bjh.19979","article-title":"JAK2 is a critical therapeutic target in VEXAS syndrome treated with ruxolitinib","volume":"206","author":"Ceccardi","year":"2025","journal-title":"Br J Haematol"},{"key":"R53-20251204","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/ard-2023-224819","article-title":"Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry","volume":"83","author":"De Valence","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R54-20251204","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s10020-024-00922-8","article-title":"Navigating therapeutic challenges in VEXAS syndrome: exploring IL-6 and JAK inhibitors at the forefront","volume":"30","author":"Li","year":"2024","journal-title":"Mol Med"},{"key":"R55-20251204","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/rheumatology\/kead697","article-title":"Treatment experiences with focus on IL-6R inhibition in patients with VEXAS syndrome and a case of remission with azacytidine treatment","volume":"64","author":"Johansen","year":"2025","journal-title":"Rheumatology"},{"key":"R56-20251204","doi-asserted-by":"crossref","DOI":"10.1016\/j.ard.2025.05.021","article-title":"Disease trajectories and glucocorticoid exposure in VEXAS syndrome treated with cytokine-directed therapies","author":"Turturice","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R57-20251204","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/bjh.17893","article-title":"Azacitidine for patients with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry","volume":"196","author":"Comont","year":"2022","journal-title":"Br J Haematol"},{"key":"R58-20251204","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s00277-023-05611-w","article-title":"VEXAS syndrome: complete molecular remission after hypomethylating therapy","volume":"103","author":"Sockel","year":"2024","journal-title":"Ann Hematol"},{"key":"R59-20251204","doi-asserted-by":"crossref","first-page":"5935","DOI":"10.1007\/s00277-024-06072-5","article-title":"Case report: VEXAS syndrome with excellent response to treatment with azacitidine","volume":"103","author":"Porges","year":"2024","journal-title":"Ann Hematol"},{"key":"R60-20251204","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.3324\/haematol.2024.285519","article-title":"De-escalation of corticosteroids and clonal remission in UBA1 mutation-driven VEXAS syndrome with 5-azacytidine","volume":"109","author":"Trikha","year":"2024","journal-title":"Haematologica"},{"key":"R61-20251204","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/bjh.19953","article-title":"Hypomethylating agents for patients with VEXAS without myelodysplastic syndrome: clinical outcome and longitudinal follow-up of vacuolization and UBA1 clonal dynamics","volume":"206","author":"\u00c1lamo","year":"2025","journal-title":"Br J Haematol"},{"key":"R62-20251204","first-page":"1432","article-title":"Very long-term remission with azacitidine in VEXAS syndrome","volume":"110","author":"Zhao","year":"2025","journal-title":"Haematologica"},{"key":"R63-20251204","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1002\/hem3.129","article-title":"Long-term genetic and clinical remissions after cessation of azacitidine treatment in patients with VEXAS syndrome","volume":"8","author":"Aalbers","year":"2024","journal-title":"Hemasphere"},{"key":"R64-20251204","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1182\/blood.2024028133","article-title":"Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX","volume":"146","author":"Jachiet","year":"2025","journal-title":"Blood"},{"key":"R65-20251204","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1007\/s00277-024-05750-8","article-title":"Could it be VEXAS?","author":"Guerineau","year":"2024","journal-title":"Ann Hematol"},{"key":"R66-20251204","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjh.20157","article-title":"Erythroid-stimulating agents in VEXAS syndrome: a retrospective study from an Italian multicentre cohort","volume":"207","author":"Diral","year":"2025","journal-title":"Br J Haematol"},{"key":"R67-20251204","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1182\/bloodadvances.2023012478","article-title":"Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT","volume":"8","author":"Gurnari","year":"2024","journal-title":"Blood Adv"},{"key":"R68-20251204","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1007\/s10067-024-07160-7","article-title":"Allogenic haematopoietic stem cell transplantation in VEXAS: A review of 33 patients","volume":"43","author":"Ali","year":"2024","journal-title":"Clin Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001137","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T15:00:36Z","timestamp":1764860436000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001137","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"type":"print","value":"1040-8711"},{"type":"electronic","value":"1531-6963"}],"subject":[],"published":{"date-parts":[[2025,11,5]]}}}